(NASDAQ: TRVI) Trevi Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 81.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Trevi Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast TRVI's revenue for 2027 to be $3,799,437,876, with the lowest TRVI revenue forecast at $3,799,437,876, and the highest TRVI revenue forecast at $3,799,437,876. On average, 1 Wall Street analysts forecast TRVI's revenue for 2028 to be $37,933,490,333, with the lowest TRVI revenue forecast at $37,933,490,333, and the highest TRVI revenue forecast at $37,933,490,333.
In 2029, TRVI is forecast to generate $24,149,568,115 in revenue, with the lowest revenue forecast at $4,335,256,038 and the highest revenue forecast at $73,480,154,307.